{
    "clinical_study": {
        "@rank": "23387", 
        "arm_group": [
            {
                "arm_group_label": "INCB040093", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "INCB040093 in combination with INCB039110", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be conducted in three parts. Part 1 is a dose escalation phase to determine\n      the maximum tolerated dose (MTD) of INCB040093, a PI3K\u03b4 inhibitor, or a tolerated,\n      pharmacologically active dose; Part 2 will evaluate the combination of INCB040093 and\n      INCB039110, a JAK1 inhibitor, to determine the MTD of the combination or a tolerated dose\n      that produces substantial pharmacologic inhibition of both targets; Part 3 will further\n      evaluate the chosen doses of INCB040093 alone and in combination with INCB039110 in subjects\n      with relapsed/refractory B-cell malignancies."
        }, 
        "brief_title": "Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "B-cell Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows:\n\n               -  Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma EXCLUDING: Burkitt\n                  lymphoma and precursor B-lymphoblastic leukemia/lymphoma INCLUDING: any\n                  non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell\n                  subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell\n                  lymphoma, transformed NHL histologies, etc.\n\n               -  Hodgkin's lymphoma\n\n          -  Life expectancy of 12 weeks or longer.\n\n          -  Subject must have received \u2265 1 prior treatment regimen.\n\n          -  The subject must not be a candidate for potentially curative therapy,  including stem\n             cell transplant.\n\n        Exclusion Criteria:\n\n          -  Received an investigational study drug within 28 days or 5 half-lives (whichever is\n             longer) prior to receiving the first dose of study drug.\n\n          -  Received any approved anticancer medications within 21 days or 5 half-lives\n             (whichever is longer) prior to receiving their first dose of study drug (42 days for\n             nitrosoureas) EXCEPT steroids at \u2264 10 mg prednisone daily (or equivalent).\n\n          -  Has any unresolved toxicity \u2265 Grade 2 from previous anticancer therapy.\n\n          -  Has history of brain metastases or spinal cord compression, or lymphoma involving the\n             central nervous system.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of \u2265 3.\n\n          -  Received allogeneic hematopoietic stem cell transplant within the last 6 months, or\n             has active graft versus host disease (GVHD) following allogeneic transplant, or is\n             currently receiving immunosuppressive therapy following allogeneic transplant.\n\n          -  Received autologous hematopoietic stem cell transplant within the last 3  months.\n\n          -  Laboratory Parameters:\n\n               -  Has any of the following laboratory values at screening unless resulting from\n                  underlying malignancy:\n\n                    1. Hemoglobin \u2264 9.0 g/dL (in no case \u2264 8.0 g/dL)\n\n                    2. Platelet count \u2264 100 x 109/L (in no case < 50 x 109/L)\n\n                    3. Absolute neutrophil count (ANC) \u2264 1.50 x 109/L (in no case < 1.0 x 109/L)\n\n               -  Has any of the following laboratory results at screening irrespective of\n                  causality:\n\n                    1. Conjugated bilirubin \u2265 1.2 x upper limit of normal (ULN) (need only be\n                       tested if total bilirubin exceeds ULN)\n\n                    2. Alkaline phosphatase (ALP) \u2265 2.5 x ULN (or \u2265 5 x ULN if bone metastases are\n                       present and hepatic parenchymal metastases are absent)\n\n                    3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \u2265 2.0 x\n                       ULN.\n\n                    4. Creatinine clearance of < 50 mL/min based on Cockroft-Gault formula.\n\n          -  Known history of infection with the human immunodeficiency virus (HIV).\n\n          -  History of active hepatitis or positive serology for hepatitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905813", 
            "org_study_id": "INCB 40093-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "INCB040093", 
                "description": "Escalating doses starting at 100 mg every day (QD)", 
                "intervention_name": "INCB040093", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "INCB040093", 
                "description": "INCB040093 monotherapy - dose to be determined at completion of Phase I of the study", 
                "intervention_name": "INCB040093", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "INCB040093 in combination with INCB039110", 
                "description": "INCB040093 dose to be determined at completion of Part 1 of the study  + INCB039110 at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.", 
                "intervention_name": "INCB040093 + INCB039110", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies", 
        "overall_contact": {
            "last_name": "Incyte Corporation Call Center", 
            "phone": "1.855.463.3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Lance Leopold, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability of INCB040093 as monotherapy  and when given in combination with INCB039110 as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events during cycle 1", 
            "safety_issue": "Yes", 
            "time_frame": "Measured every 3 weeks until progression."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Preliminary efficacy as assessed by Overall Response Rate (ORR) as measured by published criteria for Hodgkin's/non-Hodgkin's lymphoma (Cheson et al 2007 and Owen et al 2013) and Chronic Lymphocytic Leukemia (CLL) (Cheson et el 2012)", 
                "safety_issue": "No", 
                "time_frame": "Every 12 weeks (4 cycles) until progression."
            }, 
            {
                "description": "Plasma concentrations of each INCB040093 and INCB039110 will be used to estimate peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).", 
                "measure": "Pharmacokinetic (PK) collections.", 
                "safety_issue": "No", 
                "time_frame": "Measured for each patient at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15"
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}